Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix

S Tangjitgamol, S Manusirivithaya… - Journal of Obstetrics …, 2007 - Wiley Online Library
S Tangjitgamol, S Manusirivithaya, N Choomchuay, S Leelahakorn, T Thawaramara…
Journal of Obstetrics and Gynaecology Research, 2007Wiley Online Library
The prognosis of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix is
generally poor despite multimodality of treatments. We report a case of advanced stage
cervical LCNEC that showed definite response to paclitaxel/carboplatin, resulting in years of
survival. The patient was referred to our institution after undergoing a simple hysterectomy
with bilateral salpingo‐oophorectomy in her local hospital because of a ruptured metastatic
ovarian mass. She declined pelvic radiation treatment, so adjuvant chemotherapy (six cycles …
Abstract
The prognosis of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix is generally poor despite multimodality of treatments. We report a case of advanced stage cervical LCNEC that showed definite response to paclitaxel/carboplatin, resulting in years of survival. The patient was referred to our institution after undergoing a simple hysterectomy with bilateral salpingo‐oophorectomy in her local hospital because of a ruptured metastatic ovarian mass. She declined pelvic radiation treatment, so adjuvant chemotherapy (six cycles of paclitaxel/carboplatin) was given for the residual pelvic nodal diseases. Clinical complete remission was obtained, with a disease‐free period of 19 months. Systemic recurrent diseases also showed partial response to the same drug regimen for months with only minimal toxicity. However, she subsequently had progressive diseases in the liver and brain and finally died at 44 months after primary diagnosis and 19 months after recurrent diseases.
Wiley Online Library
以上显示的是最相近的搜索结果。 查看全部搜索结果